Mizuho Markets Americas LLC Sells 7,323 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• Mizuho Markets Americas LLC has reduced its stake in Johnson & Johnson by 44.6%, now holding 9,093 shares valued at approximately $1.5 million as per its recent SEC filing.
• Johnson & Johnson's latest quarterly earnings reported an EPS of $2.77, exceeding estimates and showing a 5.8% increase in revenue year-over-year.
• The company has declared a quarterly dividend of $1.30 per share, providing a yield of 3.0% for shareholders of record on August 26th.

Mizuho Markets Americas LLC decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 44.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,093 shares of the company's stock after selling 7,323 shares during the period. Mizuho Markets Americas LLC's holdings in Johnson & Johnson were worth $1,508,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares in the last quarter. von Borstel & Associates Inc. bought a new position in Johnson & Johnson in the 1st quarter valued at $49,000. Capital A Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $50,000. Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson in the 1st quarter valued at $52,000. Finally, Accredited Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $58,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on JNJ. Barclays boosted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Raymond James Financial lowered their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Royal Bank Of Canada boosted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Finally, Guggenheim reiterated a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded down $1.03 during mid-day trading on Tuesday, reaching $172.79. 7,872,042 shares of the company were exchanged, compared to its average volume of 9,065,147. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $416.14 billion, a PE ratio of 18.48, a PEG ratio of 2.21 and a beta of 0.41. The company's 50 day moving average price is $159.63 and its 200 day moving average price is $157.79. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $174.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.